Guided Therapeutics (GTHP) Stock Price, News & Analysis

Company Overview

Guided Therapeutics, Inc. is a medical device company focused on the development and commercialization of non-invasive optical diagnostic systems for the early detection of cancer and other diseases. The company’s flagship product, LuViva® Advanced Cervical Scan, employs multispectral fluorescence and reflectance spectroscopy to identify pre-cancerous and cancerous lesions on the cervix. Designed for point-of-care use, LuViva® aims to provide physicians with immediate diagnostic information to support clinical decision-making.

LuViva® operates by emitting safe levels of light onto cervical tissue and analyzing the resulting spectral signatures to distinguish between normal and abnormal cells. This approach allows for rapid, chairside screening without the need for consumables or extensive laboratory processing. Guided Therapeutics holds multiple patents covering its proprietary optical technology and data analysis algorithms. The company is also exploring additional applications for its platform in other areas of women’s health and dermatology.

Founded in 1993 and headquartered in Dallas, Texas, Guided Therapeutics has navigated the regulatory landscape to secure FDA clearance for LuViva® and is actively pursuing reimbursement pathways and strategic partnerships. While its primary market is the United States, the company is evaluating opportunities for commercialization in Europe and other international regions where cervical cancer screening protocols could benefit from non-invasive adjunctive technologies.

Guided Therapeutics is led by President and Chief Executive Officer Kurt Hagen, a medical device executive with more than two decades of experience in product development, regulatory affairs, and commercialization. The management team combines expertise in engineering, clinical research, and healthcare operations. Guided by a board of directors with backgrounds in life sciences investment and diagnostics, the company continues to advance its goal of improving patient care through innovative optical screening solutions.

Key Stats

• Today's Range: $0.26 to $0.26
• 50-Day Range: $0.09 to $0.28
• 52-Week Range: $0.06 to $0.32
• Volume: N/A
• Average Volume: 6,677 shs
• Market Capitalization: $20.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Guided Therapeutics Stock Analysis - MarketRank™

Guided Therapeutics scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Guided Therapeutics.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Guided Therapeutics is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Guided Therapeutics is -5.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of Guided Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Guided Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guided Therapeutics has recently decreased by 24.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guided Therapeutics does not currently pay a dividend.

Dividend Growth

Guided Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.02% of the float of Guided Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Guided Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Guided Therapeutics has recently decreased by 24.24%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Guided Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Guided Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

66.83% of the stock of Guided Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.69% of the stock of Guided Therapeutics is held by institutions.

GTHP Stock Analysis - Frequently Asked Questions

How have GTHP shares performed this year?

Guided Therapeutics' stock was trading at $0.15 on January 1st, 2025. Since then, GTHP stock has increased by 73.3% and is now trading at $0.26.

How were Guided Therapeutics' earnings last quarter?

Guided Therapeutics Inc. (OTCMKTS:GTHP) posted its earnings results on Thursday, May, 15th. The company reported ($0.01) earnings per share (EPS) for the quarter.

How do I buy shares of Guided Therapeutics?

Shares of GTHP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guided Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guided Therapeutics investors own include Cornerstone Strategic Investment Fund (CLM), Intel (INTC), Beam Therapeutics (BEAM), ChargePoint (CHPT), CSX (CSX), Warner Bros. Discovery (DISCA) and Enbridge (ENB).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:GTHP
• CIK: 924515
• Web: www.guidedinc.com
• Phone: (770) 242-8723
• Fax: 770-242-8639
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.42 million
• Net Margins: N/A
• Pretax Margin: -244,200.00%
• Return on Equity: N/A
• Return on Assets: -197.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.03

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 2,066.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.12) per share
• Price / Book: -2.17

Miscellaneous

• Outstanding Shares: 79,470,000
• Free Float: 26,360,000
• Market Cap: $20.66 million
• Optionable: Not Optionable
• Beta: 0.11